For your adult patients with platinum-responsive advanced ovarian cancer1
Overall population (N=733)
(HR, 0.62; 95% CI, 0.50-0.76; P<0.0001)
HRd population (n=373)
(HR, 0.43; 95% CI, 0.31-0.59; P<0.0001)
PRIMA enrolled a broad range of patient subgroups in 1L maintenance. ZEJULA is approved for all of them.